Skip to main content
main-content

Bone diseases

Medications

Osteoporosis therapy: Drug holiday or not?

Malachi McKenna explains the risks of long-term bisphosphonate therapy in patients with osteoporosis, and the rationale for a drug holiday. He also compares bisphosphonates with denosumab, and explains why denosumab should not be followed by a drug holiday.

18-02-2019 | Osteoporosis | Editorial | Article

Osteoporosis therapy: Drug holiday or not?

Malachi McKenna explains the risks of long-term bisphosphonate therapy in patients with osteoporosis, and the rationale for a drug holiday. He also compares bisphosphonates with denosumab, and explains why denosumab should not be followed by a drug holiday.

Support for denosumab as a treatment option for osteoporosis in patients treated with glucocorticoids

Kenneth Saag discusses his findings of a superior bone mineral density benefit at 2 years with denosumab versus risedronate in patients with glucocorticoid-related osteoporosis (4:45).

27-10-2018 | Denosumab | ACR/ARHP 2018 | Video

Support for denosumab as a treatment option for osteoporosis in patients treated with glucocorticoids

Kenneth Saag discusses his findings of a superior bone mineral density benefit at 2 years with denosumab versus risedronate in patients with glucocorticoid-related osteoporosis (4:45).

24-10-2018 | Osteoporosis | ACR/ARHP 2018 | News

Two-year data support denosumab use in patients with glucocorticoid-induced osteoporosis

Greater increases in bone mineral density seen with denosumab versus risedronate in glucocorticoid-treated patients with osteoporosis are sustained through 24 months, indicate phase III data.

No benefit of vitamin D supplementation for musculoskeletal health

The use of vitamin D supplements for maintaining or improving musculoskeletal health is not warranted, suggest the findings of an updated systematic review and meta-analysis.

08-10-2018 | Vitamin D | News

No benefit of vitamin D supplementation for musculoskeletal health

The use of vitamin D supplements for maintaining or improving musculoskeletal health is not warranted, suggest the findings of an updated systematic review and meta-analysis.

Zoledronate benefits postmenopausal women with osteopenia

Treatment with zoledronate once every 18 months significantly reduces the risk for nonvertebral or vertebral fragility fractures, compared with placebo, in postmenopausal women with osteopenia, study findings indicate.

02-10-2018 | Osteopenia | Highlight | News

Zoledronate benefits postmenopausal women with osteopenia

Treatment with zoledronate once every 18 months significantly reduces the risk for nonvertebral or vertebral fragility fractures, compared with placebo, in postmenopausal women with osteopenia, study findings indicate.

Proton pump inhibitors’ use and risk of hip fracture: A systematic review and meta-analysis

This systematic review and meta-analysis were performed with the aim to quantify the risk of hip fracture associated with proton pump inhibitor use [read more].
Hussain S et al. Rheumatol Int 2018. doi: 10.1007/s00296-018-4142-x

29-08-2018 | Osteoporosis | Review | Article

Proton pump inhibitors’ use and risk of hip fracture: A systematic review and meta-analysis

Hussain S et al. Rheumatol Int 2018. doi: 10.1007/s00296-018-4142-x

Medication persistence and risk of fracture among female Medicare beneficiaries diagnosed with osteoporosis

This study aimed to examine the relationship between medication persistence and fracture risk among female Medicare beneficiaries diagnosed with osteoporosis [read more].
Liu J et al. Osteoporos Int 2018. doi: 10.1007/s00198-018-4630-6

31-07-2018 | Osteoporosis | News

'Dismal' rates of osteoporosis treatment initiation after hip fracture

The proportion of patients initiating osteoporosis medication following hip fracture has declined in recent years, despite treatment reducing subsequent fracture risk, analysis of a US medical claims database suggests.

30-07-2018 | Osteoporosis | Review | Article

Glucocorticoid-induced osteoporosis: Update on management

Jagpal A, Saag KG. Curr Treat Options in Rheum 2018. doi: 10.1007/s40674-018-0105-3

23-07-2018 | Osteoporosis | Article

Incidence, risk factors, and fracture healing of atypical femoral fractures: A multicenter case-control study

Lim SJ et al. Osteoporos Int 2018. doi: 10.1007/s00198-018-4640-4

18-07-2018 | Osteoporosis | Article

Medication persistence and risk of fracture among female Medicare beneficiaries diagnosed with osteoporosis

Liu J et al. Osteoporos Int 2018. doi: 10.1007/s00198-018-4630-6

17-07-2018 | Osteoporosis | Review | Article

Denosumab in the treatment of glucocorticoid-induced osteoporosis

Coskun Benlidayi I. Rheumatol Int 2018. doi: 10.1007/s00296-018-4106-1

26-06-2018 | Osteoporosis | News

USPSTF issues recommendations for osteoporosis screening

The US Preventive Services Task Force has published a recommendation statement on screening for osteoporosis to reduce fracture risk.

26-06-2018 | Osteoporosis | Article

Clinical characteristics and bisphosphonates treatment of rare pregnancy- and lactation-associated osteoporosis

Li L et al. Clin Rheumatol 2018. doi: 10.1007/s10067-018-4185-0

image credits